前列腺素E_1脂微球制剂与贝那普利联合治疗糖尿病肾病的疗效观察

Treatment of diabetic nephropathy with combination of liposomal PGE_1 and benazepril

目的观察前列腺素E1脂微球制剂(Lipo PGE1)与贝那普利联合治疗早期糖尿病肾病(DN)和肾功能正常的临床DN的疗效。方法将76例DN患者随机分为对照组(贝那普利)和治疗组(贝那普利+Lipo PGE1)。比较两组治疗前和治疗8周后尿微白蛋白排泄率(UAER)、血肌酐(Scr)和尿素氮(BUN)等指标的变化。结果治疗后治疗组和对照组UAER均显著下降(P<0.05),治疗组比对照组下降更为明显(P<0.05);治疗组治疗后Scr水平下降,与治疗前相比有显著性差异(P<0.05);治疗后两组BUN、空腹血糖(FBG)、平均动脉压(MAP)、总胆固醇(TC)和三酰甘油(TG)均无明显变化。结论Lipo PGE1和贝那普利联合治疗可快速降低DN患者尿白蛋白排泄率,改善肾功能,疗效稳定,使用安全,无明显不良反应。

Objective To study the efficacy of combination of liposomal prostaglandin E1 （ Lipo PGE1 ） and benazepril in treatment of early diabetic nephropathy （DN） and clinical DN with normal renal function. Methods 76 cases of type 2 diabetes mellitus with DN were randomly allocated into control group （ with benazepril ） and trial group （ with benazepril and Lipo PGE1 ）. Findings of urinary albumin excretion rate （UAER） , serum levels of creatinine and BUN were examined and they were compared between these two groups before treatment and eight weeks after treatment. Results UAER had been significantly decreased in both groups （ P 〈 0.05 ） , and it was more significant in trial group than that in control group （ P 〈 0.05 ）. Serum creatinine level had been significantly decreased in trial group （ P 〈 0.05 ）. Serum creatinine level was not significantly decreased in control group during the follow -up period （ P 〉 0.05 ）. There was no significant decrease in serum levels of BUN, FBG, MAP, TC and TG seen in both groups. Conclusion Combination of Lipo PGE1 and benazepril can rapidly decrease UAER and improve renal function of patients with early DN and clinical DN with normal renal function. They are stable in improving renal function without obvious adverse reactions.